![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEW HOT TOPICS IN FEMALE INFERTILITY
Panminerva Medica 2019 March;61(1):42-51
DOI: 10.23736/S0031-0808.18.03537-1
Copyright © 2018 EDIZIONI MINERVA MEDICA
language: English
Advances in ovulation trigger strategies
Carlos DOSOUTO 1, 2 ✉, Thor HAAHR 3, 4, Peter HUMAIDAN 3, 4
1 Department of Obstetrics, Gynecology and Reproductive Medicine, Santa Creu I Sant Pau Hospital, Puigvert Foundation, Barcelona, Spain; 2 Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain; 3 The Fertility Clinic Skive Regional Hospital, Skive, Denmark; 4 Faculty of Health, Aarhus University, Aarhus, Denmark
Ovulation trigger (OT) strategy is a cornerstone in modern patient-tailored in-vitro fertilization treatment, securing the optimal number of mature oocytes retrieved without compromising fertilization, embryo development and euploidy rates. Moreover, the OT strategy is taken into consideration before selecting fresh or frozen embryo transfer (freeze-all) to obtain optimal reproductive outcomes while maintaining a low risk of ovarian hyperstimulation syndrome. Several OT agents have been proposed, however, the most common agents used in modern IVF are human chorionic gonadotropin and gonadotropin-releasing hormone agonist. As no OT agent can be generally recommended for universal use, this review evaluates different OT strategies in different clinical scenarios, discussing both the biological plausibility and the clinical evidence.
KEY WORDS: Chorionic gonadotropin - Fertilization in vitro - Ovarian hyperstimulation syndrome